Albireo Pharma Inc. (ALBO)
Company Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.
It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.
The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat.
Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | May 11, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Ronald H. W. Cooper |
Contact Details
Address: 10 Post Office Square Boston, Massachusetts United States | |
| Website | https://www.albireopharma.com |
Stock Details
| Ticker Symbol | ALBO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001322505 |
| CUSIP Number | 01345P106 |
| ISIN Number | US01345P1066 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | Chief Executive Officer, Pres & Director |
| Jason G. Duncan | Chief Legal Officer, Gen. Counsel & Sec. |
| Joan Connolly | Chief Technology Officer |
| Simon Nicolas Reade Harford | Chief Financial Officer & Treasurer |
| Dr. Jan P. Mattsson Ph.D. | Chief Scientific Officer, MD (Sweden) & Co-Founder |
| Dr. Kristina Torfgard | Vice President & Global Project Head |
| Dr. Per-Goran Gillberg Ph.D. | Co-Founder & Vice President of Devel. |
| Martha J. Carter | Chief Regulatory Officer |
| Michelle Graham | Chief HR Officer |
| Pamela Stephenson M.P.H. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Apr 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Mar 14, 2023 | 15-12G | Filing |
| Mar 08, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Mar 03, 2023 | 4 | Filing |
| Mar 02, 2023 | 4 | Filing |
| Mar 02, 2023 | 4 | Filing |
| Mar 02, 2023 | 4 | Filing |
| Mar 02, 2023 | 4 | Filing |
| Mar 02, 2023 | 4 | Filing |